Condition: SLE · Systemic Sclerosis · IIM · Sponsor: Nanjing Bioheng Biotech Co., Ltd.
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with active SLE, SSc, AAV, IIM, NMOSD, MS, MG
This description comes directly from the study's public registry record.
Xiao Shi · +86 18652756469 · xiao.shi@bioheng.com
Always discuss trial participation with your own doctor first.
| The First People's Hospital of Lianyungang | Lianyungang, Jiangus, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06775912